OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

Research and Development

PharmaTher is focused on the research and development of psychedelic pharmaceuticals for FDA approval by finding new uses and drug combinations with panaceAI™ our artificial intelligence drug repurposing platform, novel delivery systems.  We are building our product pipeline that targets disorders of the brain and nervous system, which will benefit from the attractive regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway and orphan drug, fast track and breakthrough designations.
Picture

Discovery

Artificial Intelligence for new uses of psychedelics and combinations with FDA drugs
Picture

Development

R&D in combining psychedelics with FDA approved drugs
Picture

Delivery

Novel microneedle delivery system for psychedelics

Connect With Us

Picture
Picture
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1
Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT


Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2023.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.